Rhythm Biosciences Limited

Equities

RHY

AU000000RHY2

Biotechnology & Medical Research

Market Closed - Australian S.E. 02:10:46 2024-04-19 am EDT 5-day change 1st Jan Change
0.093 AUD 0.00% Intraday chart for Rhythm Biosciences Limited 0.00% -31.11%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Rhythm Biosciences Receives AU$2.5 Million Under Rights Issue; Shares Up 3% MT
Rhythm Biosciences Limited(ASX:RHY) dropped from S&P/ASX All Ordinaries Index CI
Rhythm Biosciences Limited(ASX:RHY) dropped from S&P/ASX Emerging Companies Index CI
Rhythm Biosciences Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Rhythm Biosciences Seeks to Raise AU$6.6 Million Via Rights Offer; Shares Fall 29% MT
Rhythm Biosciences Limited Announces Resignation of Rachel David as Non-Executive Director CI
Rhythm Biosciences Ltd Announces the Appointment of James Barrie as Joint Company Secretary, Effective 1 January 2024 CI
Rhythm Biosciences Identifies Lung Cancer Biomarkers from Blood Samples; Shares Fall 6% MT
Rhythm Biosciences Limited Announces Resignation of Paul Smith as CFO CI
Rhythm Biosciences Limited Announces Executive Changes CI
Rhythm Biosciences Receives First Tranche of R&D Tax Rebate MT
Rhythm Biosciences' Breast Cancer Diagnostic Test Shows Positive Results MT
Rhythm Biosciences Joins Forces to Automate Cancer Test Kit MT
Rhythm Biosciences Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Rhythm Biosciences Appoints Director to Newly Created Deputy Chair Role MT
Rhythm Biosciences Signs Deal for UK Entry of Cancer Test MT
Rhythm Biosciences Secures UK Certification for Diagnostic Test; Shares Surge 89% MT
Rhythm Biosciences CEO Steps Down; Shares Slump 13% MT
Rhythm Biosciences Limited Announces Management Changes CI
Rhythm Biosciences Ltd Announces Executive Changes CI
Rhythm Biosciences Pulls Out TGA Submission for Colorectal Cancer Diagnostic Kit MT
Rhythm Biosciences Limited Provides Update to TGA Submission for ColoSTAT® Test-Kit CI
Rhythm Biosciences Shares Suspended from Australian Bourse MT
Rhythm Biosciences Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI
Rhythm Biosciences Retains ISO Certification MT
Chart Rhythm Biosciences Limited
More charts
Rhythm Biosciences Limited is an Australia-based medical diagnostics company. The Company is engaged in the development and commercialization of Australian medical diagnostics technology for sale in domestic and international markets. The Company's ColoSTAT a blood-base cancer test, designed for the early detection of colorectal cancer, has been developed initially as an alternative screening test for individuals unable to or unwilling to use available screening modalities. ColoSTAT is indicated to screen adults, aged 40 to 85, at average risk for developing Colorectal Cancer (CRC). The test-kit measures five specific biomarkers in the blood that either increase or decrease in quantity when CRC tumors are present.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. RHY Stock
  4. News Rhythm Biosciences Limited
  5. Rhythm Biosciences Completes Initial Biomarker Review for Core Cancer Detection Technology